样式: 排序: IF: - GO 导出 标记为已读
-
Access from healthcare professionals to evidence-based pharmacotherapy in allergy management. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-04-15 Daniela Carvalho
Access to evidence-based pharmacotherapy (EBP) is crucial in effectively managing allergies. Allergy conditions, including rhinitis, asthma, and dermatitis, require treatment guided by scientific evidence. However, healthcare professionals face challenges in accessing relevant information.
-
What molecular allergy teaches us about genetics and epidemiology of allergies. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-04-12 Benedetta Biagioni, Enrico Scala, Lorenzo Cecchi
To delineate pertinent information regarding the application of molecular allergology within the realm of both genetic and epidemiological facets of allergic diseases.
-
Biological treatments in childhood asthma. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-04-02 Antonio Nieto-García, María Nieto-Cid, Ángel Mazón-Ramos
The aim is to update the information currently available for the use of biologics in severe asthma in children, in order to facilitate their prescription as far as possible.
-
Perspectives in precautionary allergen labelling of prepackaged foods after the FAO/WHO consultation. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-03-29 Vincenzo Fierro, Carmen Mazzuca, Sara Urbani, Lamia Dahdah, Veronica Calandrelli, Rocco Luigi Valluzzi, Dinardo Giulio
The purpose of this review is to provide an overview of the perspectives regarding precautionary allergen labelling (PAL) of prepackaged foods following the consultation conducted by the Food and Agriculture Organization (FAO) and the WHO.
-
New biologics for food allergy. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-03-29 Jackson P Schuetz, Brent Anderson, Sayantani B Sindher
This review aims to explore role of emerging biologics, including ligelizumab, UB-221, dupilumab, and antialarmins, in food allergy management. With a focus on recent developments, we evaluate their promise in mitigating adverse events during oral immunotherapy (OIT), reducing allergic reactions, and addressing the limitations of current therapeutic options.
-
Precision medicine to personalize medicine in allergic airway disease. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-03-28 Jean Kim
The purpose of this study is to understand the approach to precision medicine and personalized medicine in the management of allergic airway disease.
-
Regular consumption following early introduction of allergenic foods and aggressive treatment of eczema are necessary for preventing the development of food allergy in children. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-03-28 Tetsuhiro Sakihara
Over the past two decades, food allergy prevention strategies have shifted from 'delayed introduction' to 'no delayed introduction' to 'early introduction' of allergenic foods. This article reviews important research in this field published in the early 2020s to support future strategies for food allergy prevention.
-
Management of food allergy based on oral food challenge. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-03-28 Seijiro Ishibashi, Noriyuki Yanagida, Sakura Sato, Motohiro Ebisawa
Food allergy is a growing health problem that affects both patients and society in multiple ways. Despite the emergence of novel diagnostic tools, such as component-resolved diagnostics (CRD) and basophil activation tests (BAT), oral food challenge (OFC) still plays an indispensable role in the management of food allergies. This review aimed to highlight the indications and safety concerns of conducting
-
Role of biologics in severe food allergy. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-03-28 Giulio Dinardo, Arianna Cafarotti, Vincenzo Fierro, Maria Cristina Artesani, Cristiana Indolfi, Michele Miraglia Del Giudice, Alessandro Fiocchi
This review examine the dynamic landscape of food allergy treatment within the context of emerging biologics. Our purpose is to comprehensively evaluate the potential benefits, challenges, and transformative impact associated with the utilization of biologics in comparison to conventional therapeutic modalities.
-
Precision allergy molecular diagnosis applications in food allergy. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-03-27 Sakura Sato, Motohiro Ebisawa
Precision medicine has become important in the diagnosis and management of food allergies. This review summarizes the latest information regarding molecular allergology, an essential component of food allergy managements.
-
Global burden of pediatric asthma and rhinitis - what we have recently learned from epidemiology. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-02-22 Sergio de Jesús Romero-Tapia, Luis García-Marcos
To analyze and present recently published information on the factors that modify the burden of asthma and rhinitis in pediatric ages, such as ecological determinants; highlighting access and adherence to medications, exposure to pollutants and climate change. In addition to individual determinants such as obesity, protective & risk factors and comorbidities.
-
Is allergen immunotherapy a model of personalized treatment in pediatric respiratory allergy? Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-02-13 Gustavo Falbo Wandalsen, Fernando Monteiro Aarestrup, Dirceu Solé
To review recent evidence on allergen immunotherapy (AIT) as a model of personalized medicine in the treatment of children and adolescents with respiratory allergies.
-
Understanding the heterogeneity of childhood allergic sensitization and its relationship with asthma. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-02-08 Adnan Custovic, Darije Custovic, Sara Fontanella
To review the current state of knowledge on the relationship between allergic sensitization and asthma; to lay out a roadmap for the development of IgE biomarkers that differentiate, in individual sensitized patients, whether their sensitization is important for current or future asthma symptoms, or has little or no relevance to the disease.
-
Update on occupational allergy and asthma, to soluble platinum salts. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-02-06 Dick Heederik, Frits van Rooy
This review aims to evaluate recent literature on occupational platinum salt exposure and allergy and asthma in the context of existing evidence.
-
Health disparities in allergic diseases. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-01-31 Samantha R Jacobs, Nicole Ramsey, Mariangela Bagnato, Tracy Pitt, Carla M Davis
Healthcare disparities impact prevalence, diagnosis, and management of allergic disease. The purpose of this review is to highlight the most recent evidence of healthcare disparities in allergic conditions to provide healthcare providers with better understanding of the factors contributing to disparities and to provide potential management approaches to address them. This review comes at a time in
-
What's new in pediatric asthma and rhinitis phenotypes and endotypes? Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-01-31 Giulia Roberto, Salvatore Barberi, Gian Luigi Marseglia, Amelia Licari
This review explores the evolving landscape of pediatric asthma and rhinitis, focusing on identifying and characterizing different subtypes.
-
Endotypes of occupational asthma. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-01-31 Paola Mason, Marco Biasioli, Filippo Liviero
To describe recent findings in endotyping occupational asthma by addressing the role of specific biomarkers.
-
Epidemiology of the relationship between allergic bronchopulmonary aspergillosis and asthma. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-01-31 Matteo Maule, Joana Vitte, Francesca Ambrosani, Marco Caminati
Allergic bronchopulmonary aspergillosis (ABPA) can complicate the natural history of asthmatic patients, especially the more severe ones, worsening disease control and increasing the need for therapies, steroids in particular, and medical care. The aim of the present review is to summarize the latest epidemiological data related to the relationship between asthma and ABPA and to offer a summary of
-
Association between silicosis and autoimmune disease. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-01-25 Elizabeth Miriam Fireman, Einat Fireman Klein
There is a well established association between silica inhalational exposure and autoimmune disease, particularly in the context of intense exposure. We will provide in this article an update overview of new sources of silica dust exposure, with evidences of mechanisms from human and animal studies for association between silica and autoimmune diseases, their early detection of silicosis and new options
-
Poor statistical reporting: do we have a reason for concern? A narrative review and recommendations. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-01-18 Michal Ordak
The aim of the review conducted was to present recent articles indicating the need to implement statistical recommendations in the daily work of biomedical journals.
-
Imaging of chronic rhinosinusitis with nasal polyps in the era of biological therapies. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2024-01-11 Remo Poto, Corrado Pelaia, Antonio di Salvatore, Hesham Saleh, Guy W Scadding, Gilda Varricchi
Chronic rhinosinusitis (CRS) is a chronic inflammatory disorder of the sinonasal cavities classified into two major phenotypes: CRS with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP). The diagnosis of CRS is based on clinical symptoms associated with imaging and/or nasal endoscopy findings of mucosal inflammation.
-
Long-term outcome of occupational asthma with different etiology. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-12-22 Hille Suojalehto, Irmeli Lindström
This review summarizes the recent literature on the long-term outcome of sensitizer-induced and irritant-induced occupational asthma.
-
Upper and lower airway interactions in children. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-12-04 Fernando M de Benedictis
The aim of the present review was to highlight the interactions between rhinitis, rhinosinusitis and asthma in children and to discuss the most relevant scientific progresses in the pathophysiology and treatment of these combined conditions.
-
New causes of occupational allergic contact dermatitis. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-12-01 Meghan Clynick, Dorothy Linn Holness
Occupational allergic contact dermatitis (OACD) is an important work-related skin disease. Information about the causative agents comes from many sources, including patch test databases, registries, case series and case reports. This review summarizes new information about common causative allergens and diagnosis.
-
Chronic rhinosinusitis with nasal polyps: eosinophils versus B lymphocytes in disease pathogenesis. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-11-28 Harsha H Kariyawasam, Louisa K James
To highlight the current evidence that supports the view that eosinophils may not drive disease in chronic rhinosinusitis with nasal polyps (CRSwNP) and the emerging evidence for B cells as an important player in this disease.
-
Endotypic heterogeneity and pathogenesis in chronic rhinosinusitis. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-11-16 Junqin Bai,Bruce K Tan,Atsushi Kato
PURPOSE OF REVIEW This review aims to provide updates in realms of endotypic heterogeneity, pathogenesis at the molecular level, potential of biomarkers, and cutting-edge scope of biologics in CRS. RECENT FINDINGS High-dimensional analyses, such as transcriptomes, and machine learning, have significantly enhanced CRS endotyping, uncovering diverse pathogenetic mechanisms contributing to its heterogeneity
-
Interaction of eosinophilic and neutrophilic inflammation in patients with chronic rhinosinusitis. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-11-16 Yutong Sima,Xiangdong Wang,Luo Zhang
PURPOSE OF REVIEW In the past year, the endotype of chronic rhinosinusitis (CRS) has been studied from a new perspective. Eosinophilic and neutrophilic inflammation are not independent processes in the pathogenesis of CRS. In this review, we will focus on recent research on mixed eosinophilic-neutrophilic inflammation in CRS and discuss the mechanism and potential treatments. RECENT FINDINGS Traditionally
-
SARS-CoV-2 vaccination in primary antibody deficiencies: an overview on efficacy, immunogenicity, durability of immune response and safety. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-11-15 Gabriella Cusa,Germano Sardella,Giulia Garzi,Davide Firinu,Cinzia Milito
PURPOSE OF REVIEW This review aims to summarize the current best knowledge on the efficacy of COVID-19 vaccination in vulnerable patients affected by primary antibody deficiencies (PADs), both in patients previously infected and vaccine-immunized, focusing also on the durability, on the need for multiple booster doses and on the safety of anti-SARS-CoV-2 vaccines. RECENT FINDINGS Patients vaccinated
-
Moderate asthma: burden, mechanisms and therapeutic perspectives. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-10-26 Laura De Ferrari,Anna Maria Riccio,Fulvio Braido
PURPOSE OF REVIEW Global Initiative for Asthma (GINA) document provides a classification of asthma severity according with the current level of treatment required to achieve diseases control and underlines the limitations of this approach. In this review, we will provide an overview of recent investigations that have analyzed clinical and molecular features of moderate asthma. RECENT FINDINGS Moderate
-
Safety of allergen immunotherapy in children. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-10-18 Kristin A Schmidlin, David I Bernstein
The current review discusses allergen immunotherapy (AIT) safety in children.
-
Advances in gene therapy for inborn errors of immunity. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-10-16 Lisa M Ott de Bruin, Arjan C Lankester, Frank J T Staal
Provide an overview of the landmark accomplishments and state of the art of gene therapy for inborn errors of immunity (IEI).
-
Interstitial lung diseases in inborn errors of immunity. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-10-13 Neal P Sullivan, Nivethietha Maniam, Paul J Maglione
Our goal is to review current understanding of interstitial lung disease (ILD) affecting patients with inborn errors of immunity (IEI). This includes understanding how IEI might predispose to and promote development or progression of ILD as well as how our growing understanding of IEI can help shape treatment of ILD in these patients. Additionally, by examining current knowledge of ILD in IEI, we hope
-
Transition of care in inborn errors of immunity. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-10-06 Susan Tadros, Siobhan O Burns
This review outlines the principles of transition, summarizes current information about transition practices in inborn errors of immunity (IEI) and highlights general and specific considerations for transition of patients with these conditions.
-
Inborn errors of immunity underlying defective T-cell memory. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-10-06 David Boutboul, Capucine Picard, Sylvain Latour
T-cell memory is a complex process not well understood involving specific steps, pathways and different T-cell subpopulations. Inborn errors of immunity (IEIs) represent unique models to decipher some of these requirements in humans. More than 500 different IEIs have been reported to date, and recently a subgroup of monogenic disorders characterized by memory T-cell defects has emerged, providing novel
-
Anaphylaxis: unraveling the mysteries and new perspectives. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-10-01 Gianenrico Senna,Bianca Olivieri,Mariana Castells
-
Monogenic forms of common variable immunodeficiency and implications on target therapeutic approaches. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-09-29 Giulio Tessarin, Manuela Baronio, Vassilios Lougaris
Common variable immunodeficiency (CVID) is the most common symptomatic inborn error of immunity. The disorder is characterized by variable clinical and immunological manifestations, and, in a small minority of patients, a monogenic cause may be identified. In this review, we focalized on three different monogenic forms of CVID-like disease.
-
Atopic manifestations of inborn errors of immunity. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-09-27 Laura Sams, Sonali Wijetilleka, Mark Ponsford, Andrew Gennery, Stephen Jolles
Allergy and atopic features are now well recognized manifestations of many inborn errors of immunity (IEI), and indeed may be the hallmark in some, such as DOCK8 deficiency. In this review, we describe the current IEI associated with atopy, using a comprehensive literature search and updates from the IUIS highlighting clinical clues for underlying IEI such as very early onset of atopic disease or treatment
-
Effects of allergen immunotherapy on follicular regulatory T cells. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-09-18 Shi-Ran Sun, Yin Yao, Zheng Liu
Emerging evidence indicating that the dysfunction of T follicular regulatory (T FR ) cells contributes to excessive immunoglobulin E (IgE) production and the development of allergic diseases. Conversely, allergen immunotherapy (AIT) modulates T FR cells abundance and function to promote immune tolerance. This review focus on the role of T FR cells in allergic diseases and AIT, with the objective of
-
Neurotrophic keratitis: inflammatory pathogenesis and novel therapies. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-09-08 Denise Wajnsztajn, Lana A Faraj, Sara Sanchez-Tabernero, Abraham Solomon
Neurotrophic keratitis is a rare degenerative disease characterized by decrease or absence of corneal sensation. Neurotrophic keratitis varies from mild forms with mild epitheliopathy to severe manifestations such as corneal ulceration, melting and perforation that can lead to irreversible visual loss. The cause of neurotrophic keratitis comprises a long list of diseases, medications, congenital or
-
Epidemiology of anaphylaxis: is the trend still going up? Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-08-03 Luciana Kase Tanno, Marco Caminati, Guillaume Pouessel, Gianenrico Senna, Pascal Demoly
To understand the current global scale of anaphylaxis and identify possible strategies to increase the accuracy of epidemiological data.
-
Biologics to treat anaphylaxis. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-08-01 Barbara C Yang
The purpose of this literature review was to review the latest use of biologics in the management of anaphylaxis. The methodology was to highlight both the nonbiologic management of anaphylaxis and the biologic management and how they can be used in conjunction with each other.
-
Atopic dermatitis and ocular allergy: common mechanisms and uncommon questions. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-07-31 Debajyoti Ghosh, Tesfaye B Mersha
Atopic dermatitis (AD) and ocular allergy aka allergic eye disease (AED) are two common conditions that often coexist in patients. However, molecular connections between these two conditions are incompletely understood. While common etiologic components including Th2 immune signaling have been suggested for AD and AED, the mechanism how current Th2-targetd therapies (dupilumab, tralokinumab) for AD
-
Ocular involvement in allergic drug reactions. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-07-26 Edward Fernandez,Elizabeth Phillips,Hajirah N Saeed
PURPOSE OF REVIEW Many systemic medications have been observed to cause ocular toxicity. A subset of these reactions is thought to involve immunomodulation or a hypersensitivity reaction. As new medications are developed, ocular adverse effects are becoming increasingly prevalent. Herein we review immune-mediated drug reactions affecting they eye with special attention to the hypersensitivity mechanisms
-
Anaphylaxis due to antiallergic and antiasthmatic biologics. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-07-25 Fabiana Furci,Nicoletta Luxi,Gianenrico Senna,Gianluca Trifirò
PURPOSE OF REVIEW To provide a better understanding of the risk of anaphylaxis due to antiallergic and antiasthmatic biologics through an analysis of data reported in literature and in clinical trials, and by conducting a retrospective descriptive analysis of individual case safety reports on VigiBase, the WHO International Pharmacovigilance database. RECENT FINDINGS Analysis of the data, as described
-
Ocular surface inflammation and ectatic corneal disorders. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-07-25 Nir Erdinest, Denise Wajnsztajn, Naomi London, Abraham Solomon
Inflammatory mediators are a focus of recent corneal ectasia (CE) research and are a profound, modifiable contributor to CE in general and keratoconus (KC) in particular, opening a path to explore new methods of control. As advanced imaging technology and expanded population screening allow for earlier detection, the possibility of early intervention can profoundly change the prognosis of CE.
-
Ocular surface itch and pain: key differences and similarities between the two sensations. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-07-25 Shyamal Raolji, Preet Kumar, Anat Galor
To review the pathophysiology and treatment of ocular itch and pain, encompassing nociceptive and neuropathic categories.
-
New arrivals in anaphylaxis to foods. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-07-20 Bianca Olivieri, Isabel J Skypala
More people are excluding wheat from their diet, or turning to a more sustainable diet in which includes meat substitutes or is mainly or wholly plant-based. This increases the availability of new foods and with it the increasing likelihood of novel allergens.
-
Role of the ocular surface microbiome in allergic eye diseases invited review for current opinion in allergy & clinical immunology. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-07-18 Kara M Cavuoto, Anat Galor, Angela Y Zhu
The purpose of this review is to provide an update on emerging literature on the role of the ocular surface microbiome (OSM) in allergic eye diseases.
-
The use of environmental exposure chambers in studies related to ocular surface effects. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-07-18 Alina Gherasim, Leonard Bielory
The potential of allergen challenges using environmental exposure facilities in allergic conjunctivitis drug development and more recently its implication on the diagnosis of the united airways concept have been emphasized in the recent literature. This study aims to present an overview of new and important data in this field.
-
Editorial: pharmacotherapy and evidence-based medicine section. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-08-01 Giovanni Paoletti,Giovanni Costanzo,Lorenzo Del Moro,Federico Spataro,Palma Carlucci,Danilo Di Bona
-
Prevalence and clinical characteristics of vernal keratoconjunctivitis in sub-Saharan Africa. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-07-07 Eleanor Ngwe Nche, Marvice Muyen Okwen, Abraham Solomon
Vernal keratoconjunctivitis (VKC) is a chronic bilateral allergic inflammatory disease of the conjunctiva and cornea that affects children and young adults, especially in sub-Saharan Africa. A limbal form (tropical endemic limbo conjunctivitis) is thought to be more common in the tropics where research on this vision-impairing condition is scanty. We sought to review current literature from sub-Saharan
-
Chronic spontaneous urticaria: new evidences on the role of autoimmunity. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-07-07 Yi-Kui Xiang, Sercan Guloglu, Daniel Elieh-Ali-Komi, Emek Kocatürk
The purpose of this review is to provide an overview of the recent advancements and relevance of the autoimmune theories in chronic spontaneous urticaria (CSU).
-
The pathogenetic role of Th17 immune response in atopic dermatitis. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-06-28 Eden David, Tali Czarnowicki
As we continue to unravel the pathophysiology and immune mechanisms underlying atopic dermatitis (AD), the emergence of targeted treatments has provided new options for management. Although there are available therapies targeting various immune pathways in AD, the precise pathogenic role of interleukin (IL)-17 in AD pathogenesis remains unclear. The objective of this review is to examine the existing
-
New approaches in childhood asthma treatment. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-06-26 Riccardo Castagnoli, Ilaria Brambilla, Mattia Giovannini, Gian Luigi Marseglia, Amelia Licari
This review aims to summarize the most recent advances in asthma management, focusing on novel approaches to pediatric asthma.
-
Drug allergy in primary care: systematic review to support quality improvement initiative of management and optimization of healthcare pathways. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-06-22 Clara Gaudin, Dermot Ryan, Pascal Demoly, Luciana Kase Tanno
The aim of this study was to review the practice of general practitioners (GPs) in regard to the diagnosis and management of drug hypersensitivity reactions (DHRs) to identify major challenges and to facilitate the development of decision support tools to GPs confronted with DHRs patients.
-
Highlights of the treatment of allergic rhinitis according to Chinese guidelines. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-06-21 Min Zhang, Tian Ao, Lei Cheng
This review aimed to introduce the pharmacotherapy of allergic rhinitis according to the 2022 updated Chinese guidelines.
-
COPD and biologic treatment: state of the art. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-06-21 Sebastian Ferri, Giovanni Paoletti, Corrado Pelaia, Enrico Heffler, Giorgio Walter Canonica, Francesca Puggioni
Chronic Obstructive Pulmonary Disease (COPD) is a common, heterogeneous disease associated with abnormal inflammatory response of the lung to noxious particles and gases. The progression of disease leads to respiratory failure, disability and premature death. Although recent progress in reducing the global burden of many chronic disease, such as heart disease and cancer, mortality and morbidity due
-
Giant cell arteritis and innovative treatments. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-06-20 Giulia Costanzo, Ledda Andrea Giovanni, Sambugaro Giada
Giant cell arteritis (GCA) is an idiopathic and persistent condition characterized by granulomatous vasculitis of the medium and large vessels with overlapping phenotypes, including conventional cranial arteritis and extra-cranial GCA, also known as large-vessel GCA. Vascular problems linked with large vessel involvement may partly be caused by delayed diagnosis, emphasizing the necessity of early
-
Perioperative anaphylaxis: when the allergological work-up goes negative. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-06-20 Paul-Michel Mertes, Charles Tacquard
Perioperative anaphylaxis (POA) is rare but is associated with significant morbidity and mortality. Patients are referred to the allergist to identify the mechanism of the reaction, the causative agent and make recommendations regarding subsequent anaesthesia. Despite a well conducted allergological evaluation, the causative agent is not found in 30-60% of these reactions, leaving patients without
-
Clinical outcomes of AIT in the elderly population. Curr. Opin. Allergy Clin. Immunol. (IF 2.8) Pub Date : 2023-06-20 Andrzej Bożek
This review aims to present the current knowledge on the effectiveness and safety of allergen immunotherapy (AIT) in patients over 60 years of age with inhalant allergies.